Seegene and Springer Nature Join Forces to Revolutionize Disease Research and Diagnosis
May 18, 2024, 3:41 pm
In a groundbreaking move, Seegene Inc. and Springer Nature have announced a strategic alliance that seeks to transform the landscape of disease research and diagnosis. This partnership, forged with the aim of fostering collaboration with researchers across various disease fields, will utilize cutting-edge PCR diagnostic technology to accelerate the development of innovative diagnostic products.
The alliance between Seegene, a leading South Korean company specializing in PCR molecular diagnostics, and Springer Nature, the publisher of the prestigious scientific journal, Nature, is set to facilitate C-level cooperation and strengthen the partnership for Seegene's SG OneSystem™ business - a technology-sharing initiative aimed at advancing global healthcare.
With a shared commitment to advancing discovery and working towards a world free of diseases, Seegene and Springer Nature are poised to leverage their joint expertise and knowledge to support researchers worldwide in speeding up PCR diagnostic testing for a wide range of diseases. By tapping into the extensive network of Springer Nature, the two companies will provide funding and technology to global scientists and experts, significantly expanding the scope and potential of diagnostic products.
The strategic alliance, spearheaded by senior management at both companies, builds upon the success of the Open Innovation Program launched in 2023, which aimed to develop innovative diagnostic products through collaboration with the scientific community. Moving forward, Seegene and Springer Nature will further expand their collaboration through the OneSystem™ business, identifying and promoting potential partners and co-hosting annual symposiums to drive innovation in disease research and diagnosis.
Dr. Jong-Yoon Chun, CEO and Founder of Seegene, expressed excitement about deepening the strategic relationship with Springer Nature, a global leader in the scientific community. Together, the two companies are committed to advancing the success of the SG OneSystem™ business and realizing a world free of diseases.
Frank Vrancken Peeters, CEO of Springer Nature, commended Seegene's efforts to democratize early disease diagnosis and enable timely treatment, emphasizing the importance of collaboration in achieving this noble goal. As a trusted partner to the research community, Springer Nature is dedicated to building a global network of experts who can leverage Seegene's technology to accelerate the development of new tests for a wide range of conditions.
The inaugural Open Innovation Program launched in 2023 garnered significant interest from the global scientific community, receiving 281 applications from 47 countries for 15 projects. Recognizing the potential of technology sharing, Seegene and Springer Nature aim to expedite the commercialization of expertise and knowledge across various fields. The 2024 program will adopt a more open format, allowing applicants to propose any product development, with the goal of democratizing PCR molecular diagnostics and addressing unmet needs in healthcare.
Seegene, with 23 years of experience in R&D, manufacturing, and business around syndromic quantitative PCR technologies, has been at the forefront of COVID-19 testing, providing over 340 million tests to more than 100 countries worldwide. Springer Nature, with over 180 years of advancing discovery in the research community, is home to trusted brands like Springer, Nature Portfolio, BMC, Palgrave Macmillan, and Scientific American.
The SG OneSystem™ business is Seegene's global strategy to share its PCR molecular diagnostics technology and know-how with leading companies worldwide, aiming to create a global consortium that expands the development pipeline of PCR products. Through collaboration with Microsoft and Springer Nature, Seegene is poised to advance its Seegene Digitalized Development System (SGDDS) using cutting-edge technology, including artificial intelligence, to drive innovation in disease diagnosis.
The Open Innovation Program (OIP), a global PCR reagent development project co-hosted by Seegene and Springer Nature, aims to consolidate knowledge and expertise from scientists and experts worldwide to develop products that address unmet needs in healthcare. The program is part of Seegene's technology-sharing business, SG OneSystem™, with the goal of realizing a world free from all diseases.
Seegene Digitalized Development System (SGDDS) is a system that enables standardized and automated development of diagnostic kits, embedded with Seegene's technologies and product expertise. It provides support for researchers to develop syndromic PCR products, even for those with limited development experience.
In conclusion, the strategic alliance between Seegene and Springer Nature represents a significant step towards revolutionizing disease research and diagnosis. By leveraging their collective expertise, knowledge, and resources, the two companies are poised to drive innovation, democratize early disease diagnosis, and ultimately contribute to realizing a world free of diseases.
The alliance between Seegene, a leading South Korean company specializing in PCR molecular diagnostics, and Springer Nature, the publisher of the prestigious scientific journal, Nature, is set to facilitate C-level cooperation and strengthen the partnership for Seegene's SG OneSystem™ business - a technology-sharing initiative aimed at advancing global healthcare.
With a shared commitment to advancing discovery and working towards a world free of diseases, Seegene and Springer Nature are poised to leverage their joint expertise and knowledge to support researchers worldwide in speeding up PCR diagnostic testing for a wide range of diseases. By tapping into the extensive network of Springer Nature, the two companies will provide funding and technology to global scientists and experts, significantly expanding the scope and potential of diagnostic products.
The strategic alliance, spearheaded by senior management at both companies, builds upon the success of the Open Innovation Program launched in 2023, which aimed to develop innovative diagnostic products through collaboration with the scientific community. Moving forward, Seegene and Springer Nature will further expand their collaboration through the OneSystem™ business, identifying and promoting potential partners and co-hosting annual symposiums to drive innovation in disease research and diagnosis.
Dr. Jong-Yoon Chun, CEO and Founder of Seegene, expressed excitement about deepening the strategic relationship with Springer Nature, a global leader in the scientific community. Together, the two companies are committed to advancing the success of the SG OneSystem™ business and realizing a world free of diseases.
Frank Vrancken Peeters, CEO of Springer Nature, commended Seegene's efforts to democratize early disease diagnosis and enable timely treatment, emphasizing the importance of collaboration in achieving this noble goal. As a trusted partner to the research community, Springer Nature is dedicated to building a global network of experts who can leverage Seegene's technology to accelerate the development of new tests for a wide range of conditions.
The inaugural Open Innovation Program launched in 2023 garnered significant interest from the global scientific community, receiving 281 applications from 47 countries for 15 projects. Recognizing the potential of technology sharing, Seegene and Springer Nature aim to expedite the commercialization of expertise and knowledge across various fields. The 2024 program will adopt a more open format, allowing applicants to propose any product development, with the goal of democratizing PCR molecular diagnostics and addressing unmet needs in healthcare.
Seegene, with 23 years of experience in R&D, manufacturing, and business around syndromic quantitative PCR technologies, has been at the forefront of COVID-19 testing, providing over 340 million tests to more than 100 countries worldwide. Springer Nature, with over 180 years of advancing discovery in the research community, is home to trusted brands like Springer, Nature Portfolio, BMC, Palgrave Macmillan, and Scientific American.
The SG OneSystem™ business is Seegene's global strategy to share its PCR molecular diagnostics technology and know-how with leading companies worldwide, aiming to create a global consortium that expands the development pipeline of PCR products. Through collaboration with Microsoft and Springer Nature, Seegene is poised to advance its Seegene Digitalized Development System (SGDDS) using cutting-edge technology, including artificial intelligence, to drive innovation in disease diagnosis.
The Open Innovation Program (OIP), a global PCR reagent development project co-hosted by Seegene and Springer Nature, aims to consolidate knowledge and expertise from scientists and experts worldwide to develop products that address unmet needs in healthcare. The program is part of Seegene's technology-sharing business, SG OneSystem™, with the goal of realizing a world free from all diseases.
Seegene Digitalized Development System (SGDDS) is a system that enables standardized and automated development of diagnostic kits, embedded with Seegene's technologies and product expertise. It provides support for researchers to develop syndromic PCR products, even for those with limited development experience.
In conclusion, the strategic alliance between Seegene and Springer Nature represents a significant step towards revolutionizing disease research and diagnosis. By leveraging their collective expertise, knowledge, and resources, the two companies are poised to drive innovation, democratize early disease diagnosis, and ultimately contribute to realizing a world free of diseases.